AbCellera Biologics Inc.(ABCL)Earnings, Financials & Key RatiosAbCellera Biologics Inc. (ABCL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to generate positive free cash flow, combined with a 2026Q1 net margin of -5.2% and a rapidly depleting cash balance, suggests significant execution risk for long-term investors.
AbCellera Biologics Inc. (ABCL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
AbCellera Biologics Inc. (ABCL) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.14vs $0.22+36.4% | $8Mvs $5M+53.6% |
| Q1 2026 | Feb 24, 2026 | $0.03vs $0.18+83.3% | $45Mvs $7M+572.9% |
| Q4 2025 | Nov 6, 2025 | $0.19vs $0.17-11.8% | $9Mvs $6M+41.9% |
| Q3 2025 | Aug 7, 2025 | $0.12vs $0.17+29.4% | $17Mvs $6M+168.6% |
Recent stock market news and headlines for AbCellera Biologics Inc. (ABCL)
ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.
Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.
Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop T-cell engaging multispecific antibodies for cancer, the companies said on Wednesday.
Key metrics vs top competitors for AbCellera Biologics Inc. (ABCL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.60 | $2.32B | -15.51 | 160.56% | -194.88% | -13.33% | — | |
| $102.25 | $6.37B | -78.65 | 20.32% | -19.85% | -17.46% | — | |
| $3.67 | $1.64B | -2.55 | 26.92% | -844.46% | -54.32% | — | |
| $16.39 | $1.22B | -11.62 | 23.29% | -40.6% | -30.85% | — | |
| $33.48 | $3.44B | -41.33 | 120.01% | -49.17% | -5.89% | — | |
| $1.63 | $89.62M | -1.27 | 15.57% | -468.74% | -26.58% | — |
AbCellera Biologics Inc. (ABCL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AbCellera Biologics Inc. (ABCL) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 11, 2026·SEC
Feb 24, 2026·SEC
Jan 14, 2026·SEC
Get notified when ABCL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AbCellera Biologics Inc. (ABCL) stock FAQ — growth, dividends, profitability & financials explained
AbCellera Biologics Inc. (ABCL) reported $79.2M in revenue for fiscal year 2025. This represents a 797% increase from $8.8M in 2018.
AbCellera Biologics Inc. (ABCL) grew revenue by 160.6% over the past year. This is strong growth.
AbCellera Biologics Inc. (ABCL) reported a net loss of $144.0M for fiscal year 2025.
AbCellera Biologics Inc. (ABCL) has a return on equity (ROE) of -13.3%. Negative ROE indicates the company is unprofitable.
AbCellera Biologics Inc. (ABCL) had negative free cash flow of $189.2M in fiscal year 2025, likely due to heavy capital investments.
